Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 17/20 | 0.49 |
| ▸ | DRD2 | P14416 | 16/20 | 0.49 |
| ▸ | DRD5 | P21918 | 15/20 | 0.49 |
| ▸ | DRD3 | P35462 | 12/20 | 0.49 |
| ▸ | DRD4 | P21917 | 9/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6903685 | 0.74 | DRD1 (0.76) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL6901150 | 0.74 | DRD1 (0.73) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL7527997 | 0.73 | DRD2 (0.49) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL29034035 | 0.73 | PNMT (0.44) | DRD2CA1CA2CA4CA6 | |
| SCHEMBL6907788 | 0.69 | DRD2 (0.52) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL30346211 | 0.69 | MAOA (0.53) | CA1CA2CA4CA6 | |
| SCHEMBL5658358 | 0.69 | DRD2 (0.44) | DRD1DRD2DRD5DRD3DRD4 | |
| SCHEMBL8649269 | 0.69 | MAOA (0.53) | CA1CA2CA4CA6 | |
| SCHEMBL3675894 | 0.69 | BCL2L1 (0.50) | — | |
| SCHEMBL31634362 | 0.69 | DRD2 (0.61) | DRD1DRD2DRD5DRD3DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8029765-B2 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | MASIMO LABORATORIES, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8029765-B2 | SMMR (small molecule metabolite reporters) for use as in vivo glucose biosensors | MASIMO LABORATORIES, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090004108-A1 | Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors | MASIMO LABORATORIES, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090004108-A1 | Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors | MASIMO LABORATORIES, INC. (US) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004108-A1 | Smmr (Small Molecule Metabolite Reporters) For Use As In Vivo Glucose Biosensors | GCKR, SYMPK, SUCNR1 | DRD1 2879/4885DRD2 2992/4885DRD5 3166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.